This study indicates that regulating the expression level of PGK1 impacts the sensitivity of HER2-positive gastric cancer to lapatinib, potentially serving as a therapeutic strategy for HER2-positive gastric cancer patients who do not respond to lapatinib. Here, ERBB2 is linked to gastric cancer.